Business Wire

Covid-19 Passport from iProov and Mvine Moves Into Trial Phase

Share

Mvine and iProov announce today their design for a simple, secure and widely recognized Covid-19 immunity and vaccination passport will now move into live testing. The Mvine-iProov passport enables a person’s test result or vaccination status to be registered and proved without disclosing their identity, and without the need for extensive new infrastructure.

With additional backing from Innovate UK, which initially funded the development of a successful working prototype, the Mvine-iProov passport will now be tested by Directors of Public Health within the National Health Service (NHS) in the UK. Mvine and iProov aim to complete two trials by 31 March 2021, giving Directors of Public Health across the country the confidence to deploy the passport at scale to benefit their local areas.

Crucially, the Mvine-iProov passport can be plugged into the NHS’ existing infrastructure, enabling it to meet the specific needs of local Directors of Public Health and any overarching national requirements. This flexibility ensures that areas in different tiers or levels of vaccination rollout can set appropriate policies and enforce them with confidence.

The Mvine-iProov passport has been developed quickly and cost-efficiently, with a total £75,000 investment from Innovate UK following a call for ideas in April 2020. It is expected this investment in UK innovation will help businesses and employees return to work, and enable families and friends to reconnect, more quickly and more responsibly than would otherwise be possible.

Frank Joshi, Director at Mvine, said: “Without the need for an extensive new infrastructure, the Directors of Public Health will learn how our innovation is used to promote public health and protect citizen privacy. Unlike some other digital solutions for Covid-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead.”

Andrew Bud, CEO at iProov, said: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three. Our Genuine Presence Assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.”

ENDS

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to remotely verify customer identity. Used for onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), GovTech Singapore, Eurostar, Rabobank, ING, and others. iProov’s unique patented technology provides Genuine Presence Assurance, ensuring that an online customer is the right person, a real person, and authenticating right now. This protects against spoof attacks from photos, videos, masks and the emerging threat of deepfakes. iProov was recognized as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50 and was also named a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com

About Mvine

Mvine Limited is a British deep tech company delivering next generation platforms that power the digital economy. It is perhaps best known for its work in providing cyber-secure collaboration portals, in use in the financial services sector as virtual deal rooms and in other industries as procurement portals and as diversity/equality portals. The company has also pursued identity management and its technology is in use in the telecoms sector for federated authentication and in other industries for single sign on identity, authentication and authorization. www.mvine.com

About Innovate UK

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org

Fact Checking

The UK government announcement on 20 May 2020 to expand the funding envelope from £20 million to £40 million meant 800 funding awards could be made. The original announcement was made on 3 April 2020 by BEIS, Innovate UK and Amanda Solloway MP. The competition opened Friday 3 April 2020 and closed Friday 17 April 2020.

Contact information

Joseph Spear
joseph.spear@mvine.com

Sarah Merker
sarah.merker@iproov.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France26.1.2021 12:00:00 CETPress release

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021. Tilray products will be administered to qualifying patients in the French experiment, for whom existing treatments do not provide sufficient relief from their symptoms, and for therapeutic indications including: Neuropathic pain that is refractory to therapies currently available (drug or non-drug treatments); Certain forms of epilepsy that are drug-resistant; In certain persistent symptoms in oncology, related to cancer or anti-cancer treatment; In palliative care s

Aqua Lung Welcomes World-Renowned Wildlife Photographer and Conservationist Paul Nicklen as a Global Ocean Ambassador26.1.2021 12:00:00 CETPress release

Aqua Lung, the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, today announced world-renowned wildlife photographer and conservationist Paul Nicklen is joining the brand as a global ocean ambassador. As part of the partnership, Nicklen will exclusively use Aqua Lung, Apeks, and O.ME.R. products during all dive expeditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005122/en/ Aqua Lung global ocean ambassador and SeaLegacy co-founder, Paul Nicklen with co-founder and President of SeaLegacy, Cristina Mittermeier. Photo credit: Joe Leahy Nicklen, best-known for his incomparable underwater photography and ocean conservation efforts, will utilize the full range of industry-leading Aqua Lung, Apeks and O.ME.R. products from wetsuits, masks and fins to technical gear and regulators. Helping to grow the brand globally, Nicklen joins an elite roster of ambassadors

New Study Concludes Xlear Kills and/or Deactivates SARS-CoV-2; Efficacy Against New Variants26.1.2021 10:15:00 CETPress release

A new in vitro study done collaboratively by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the virus that causes COVID-19. The imaging research study component was performed at the BioCryo facility of Northwestern University’s NUANCE Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005436/en/ Using electron microscopy, we have visual evidence showing that xylitol and grapefruit seed extract (GSE) counters the virus. The GSE kills the virus, while the xylitol prevents the virus from attaching to the cell walls. The image shows SARS-CoV-2 viruses outside the cell and never attached, thereby preventing infection (Photo: Business Wire) The study tested SARS-CoV-2 virus titers and LRV against a single concentration of Xlear nasal spray. According to the Study, “After a 25-minute contact time, the nasal spray reduced v

Owl Labs Teams with Ingram Micro to Widen Distribution of the Meeting Owl Pro within Europe26.1.2021 09:00:00 CETPress release

Owl Labs, the award-winning leader in immersive and collaborative video conferencing technology and services, today announced an alliance with Ingram Micro, the world’s largest distributor and provider of technology services and solutions.The new distribution agreement expands Owl Labs’ reach across Europe and strengthens Owl Labs’ presence within key European markets. Through Owl Labs working relationship with Ingram Micro, Owl Labs will now be able to expand the reach and accessibility of its award-winning flagship product, the Meeting Owl Pro, to one centralised distribution warehouse in Straubing, Germany, and from that single point will support its supply chain into 17 distribution centers across Europe, trading across all 28 countries. Ingram Micro serves a diverse base of resellers and 2,000+ of the world’s most recognized IT and mobility technology brands. With the rapid adoption of hybrid work and remote teams, maintaining effective communication and collaboration regardless o

MyHeritage lanserer en fargerestaureringsfunksjon for å bringe nytt liv til falmede fargebilder26.1.2021 08:54:00 CETPressemelding

MyHeritage, som er verdens ledende tjeneste for at du skal kunne oppdage og forske din fortid og styrke din fremtid, annonsere i dag at de lanserer et verktøy for å fargerestaurere falmede fargebilder. Dette er en ytterligere forbedring av MyHeritage sin avanserte samling med fotoverktøy. Fargerestaurering gjenoppliver de autentiske fargene i falmede bilder, med eksepsjonelle resultater. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20210125005990/no/ MyHeritage lanserer en fargerestaureringsfunksjon for å bringe nytt liv til falmede fargebilder (Photo: Business Wire) Fargerestaurering er ideelt for gamle fargebilder fra 1950 til 1990-tallet. Fotografier som har vært oppbevart i fotoalbum har gjerne ikke tålt tidens tann og fargene har falmet og gule. Teknologien for fargerestaurering er lisensiert av DeOldify, og er utviklet av dyplæringsekspertene Jason Antic og Dana Kelley. Løsningen er nå integrert på MyHeritage. De

Credence MedSystems Receives a Strategic Investment From One of the World’s Leading Pharmaceutical Companies26.1.2021 07:07:00 CETPress release

Credence MedSystems announced today that Novartis has made a strategic investment in the Company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems, with an initial focus on the Credence Companion® Safety Syringe System. With the investment in Credence, Novartis seeks to support its patients, caregivers, and healthcare professionals by enhancing the safety and user experience during administration of Novartis injectable medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005138/en/ The Credence Companion allows pharmaceutical manufacturers to provide critical usability and safety features to their end-users. At the completion of the injection, the user receives end-of-dose cues indicating that the full dose has been delivered, and the needle automatically retracts into the syringe barrel. The enhanced usability can contribute to improved adherence, while

AGCO Announces Organizational Update25.1.2021 22:31:00 CETPress release

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announced intended changes and recent additions to its senior leadership team to further increase customer focus and strengthen investment in precision agriculture and digital solutions to maximize stakeholder value. Robert Crain will be the Senior Vice President leading the newly formed Customer Experience team charged with delivering the best end-to-end customer experience in the industry. Seth Crawford has joined the senior team in the new role of Senior Vice President, Precision Ag and Digital to reinforce AGCO’s commitment to delivering industry-leading, smart farming solutions. Following a successful, 22-year tenure at Deere & Company, Mr. Crawford joined AGCO in 2019 to lead its Fuse Connected Services and Technology division. Additionally, other members of the senior team will assume worldwide responsibility for AGCO’s core brands to maximize brand value